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Abstract
Plasmodium vivax is considered to be rare in the predominantly Duffy negative populations of Sub-Saharan Africa, as this
red blood cell surface antigen is essential for invasion by the parasite. However, despite only very few reports of molecularly
confirmed P. vivax from tropical Africa, serological evidence indicated that 13% of the persons sampled in Congo had been
exposed to P. vivax. We identified P. vivax by microscopy in 8 smears from Ugandan pregnant women who had been
enrolled in a longitudinal study of malaria in pregnancy. A nested polymerase chain reaction (PCR) protocol was used to
detect and identify the Plasmodium parasites present. PCR analysis confirmed the presence of P. vivax for three of the
women and analysis of all available samples from these women revealed clinically silent chronic low-grade vivax infections
for two of them. The parasites in one woman carried pyrimethamine resistance-associated double non-synonymous
mutations in the P. vivax dihydrofolate reductase gene. The three women found infected with P. vivax were Duffy positive as
were nine of 68 women randomly selected from the cohort. The data presented from these three case reports is consistent
with stable transmission of malaria in a predominantly Duffy negative African population. Given the substantial morbidity
associated with vivax infection in non-African endemic areas, it will be important to investigate whether the distribution and
prevalence of P. vivax have been underestimated in Sub-Saharan Africa. This is particularly important in the context of the
drive to eliminate malaria and its morbidity.
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Introduction
The prevalence of Plasmodium vivax in tropical African became a
matter for debate subsequent to the description of P. ovale in 1922
[1].IndeedP.ovalethat occurspredominantlyinwesternand central
Sub-Saharan Africa, has morphology in the blood that is difficult to
distinguish from that of P. vivax, particularly in thick blood smears
[2]. The accuracy of a P. vivax diagnosis in these regions was further
questioned after observations in the 1930s revealed that Americans
of African originweregenerally innately resistantto bloodinfections
by P. vivax [3],an observation that was later extended to native West
Africa residents [4]. The factor responsible for this resistance was
uncovered in 1976: P. vivax can only invade red blood cells that
express the Duffy blood group antigen on their surface [5]. Thus,
the perception took hold that little if any P. vivax transmission
occurred in the predominantly Duffy negative populations, with
close to 100% for West Africa, of Sub-Saharan countries (Eritrea,
Djibouti, Ethiopia and Somalia excepted). It has since become
customarytorecordanybenign tertianmalariaparasites originating
from these regions as P. ovale. Nonetheless, P. vivax cases determined
by microscopic examinations are reported from these predomi-
nantly Duffy negative populations [6].
The advent of sensitive and specific molecular techniques to
detect malaria parasites opened the way to distinguish P. ovale from
P. vivax confidently. The first molecularly confirmed case of P. vivax
originating from Sub-Saharan Africa was from patients returning
from the Democratic Republic of Sa ˜o Tome ´ e Prı ´ncipe, an island
in the Gulf of Guinea [7], but their Duffy status could not be
ascertained. This was followed by other reports of P. vivax
infections imported from Central or Western Africa [8,9] and
Zambia [10], or acquired locally in Guinea Equatorial [11].
Recently P. vivax parasites were detected molecularly in mosqui-
toes collected in Kenya [12]. Moreover, the paradigm of the Duffy
antigen dependence for P. vivax, was challenged by confirmed
findings of P. vivax in the blood of Duffy negative individuals in
Kenya and Brazil [12,13,14], and by the discovery of genetically
diverse population of P. vivax lines capable of infecting Duffy
negative populations in Madagascar [15].
Despite a relatively high prevalence of P. vivax in travellers
returning from Sub-Saharan Africa [7,8], the prevalence of P. vivax
was inferred to be very low in endemic residents from these
regions. Only a single case of P. vivax (from Sa ˜o Tome ´ and
Prı ´ncipe) was detected by PCR screening in 2588 blood samples
(including 851 from the Republic of Congo) from nine African
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evidence from the Republic of Congo indicated that ca. 13% of
the predominantly Duffy negative population (.95%–99%) had
been exposed to P. vivax-infected mosquitoes [17], suggesting that
significant transmission of P. vivax was sustainable in population
predominantly insusceptible to this parasite. If this were the case,
then estimates of the human population at risk from vivax malaria
[6] would need to be revised upwards.
Results
P. vivax was identified in thick blood smears (TBS) from eight of
the women in a cohort of pregnant women that were being
followed-up as part of a study of malaria in pregnancy. For all the
smears, parasitaemias were very low (,800 parasite per ml of blood,
i.e. with a maximum of 50 parasite forms observed per 500 white
blood cells). DNA was extracted from the blood samples
corresponding to these slides and analyzed by PCR. Three samples
were negative by amplification. This discrepancy, which was
unlikely to be due to low PCR assay sensitivity as this was
monitored throughout the study, was most probably due to the
combined facts that the blood samples were collected on filter paper
two or more years prior to template preparation (long storage is
associated with DNA degradation) and that the parasitaemias were
close to the limits of microscopic detection. Moreover, the template
added to each PCR reaction corresponded to a small volume of
blood, close to that scanned for thick smear examination, which
makes it likely for the PCRanalysis to fail to detectthe parasite from
suchsamples.Intwoothersamples,P.falciparum,aloneorasamixed
infection with P. ovale, was detected. For the remaining three
samples the presence of P. vivax was confirmed molecularly. DNA
was then purified from all the blood samples collected from these
three patientsduringtheirfollow-up,and subjected toPCRanalysis.
The PCR results and the TBS readings for these patients are
presented schematically (Fig. 1). The sensitivity of parasite detection
by PCR was expected to be higher for samples from C12080
(n=23) as compared that that from samples from C03430 (n=6)
and C07810 (n=6), because only dried blood spots were available
from the last two, whereas frozen RBC pellets were available for the
first. Indeed, the DNA template screened from dried blood spots
corresponded to ca. 1 ml of blood while that from frozen blood
pellets corresponded to 10 ml, probably the reason for the large
number of Plasmodium-positive samples from C12080 (Fig. 1). For
the whole set, only 15 samples were analyzed both by TBS and
PCR, and a single case of microscopic misdiagnosis was identified,
namely on the day of delivery forC03430 (Fig. 1).Thiscould be due
to the presence of very early P. vivax ring stages, where the
characteristic RBC enlargement and Schu ¨ffner dots are yet to
develop, making these forms particularly easily confused with P.
falciparum early rings in thick blood smears.
The paucity of parasites in our samples made it difficult to
genotype satisfactorily the P. vivax parasites in the various samples,
thus it was not possible to establish whether the P. vivax
populations observed at different times in the same woman or in
different women were genetically related. Nonetheless, amplifica-
tion of the fragment spanning a large portion of Pvdhfr was
successful for some of the samples collected from patient C12080
(Fig. 1), as this was considered important given the observation
that P. vivax was detected in the blood samples collected over the
weeks following administration of sulfadoxine-pyrimethamine (SP)
as apart of intermittent preventive therapy in pregnancy (IPTp).
As compared to the wild-type gene (from the Sal I line), the
fragments from all the samples shared the two non-synonymous
mutations at residues 58 (S to R) and 117 (S to N). These
mutations have been associated with resistance to pyrimethamine
[18]. Non-synonymous mutations at other residues, and in
particular 57 and 61, were not observed.
The Duffy status of the three women with P. vivax infections was
determined by RFLP-PCR to be heterozygous positive Fy(b+,b2).
In order to estimate the prevalence of Duffy positivity in the cohort,
68 randomly selected women were also genotyped. Eight were
Duffy positive heterozygous Fy(b+,b2), one was Duffy positive
homozygous Fy(a+,b+), and the remainder were Duffy negative
Fy(b2,b2). Thus, a prevalence of 13.2% (95% CI 6.6–24.1) was
estimated for Duffy positivity among the pregnant women.
Discussion
The data we present constitutes the first set of longitudinal
observations of molecularly confirmed P. vivax infections in
pregnant native Ugandan residents. Despite being confined to
three persons, the observations allow formulating some conclu-
sions and speculations. It is likely that P. vivax in Mbarara District
is transmitted in a stable manner because the three women
harbouring this parasite in their blood were recruited many
months apart (May 2007 for C03430, November 2007 for
C07810, and December 2008 for C12080). This is consistent
with the conclusion derived from the studies conducted in Pointe-
Noire, Republic of Congo, namely that P. vivax transmission could
be maintained by a minority of Duffy positive (hetero- or
homozygous) individuals [17]. In a previous study, PCR analysis
failed to reveal the presence of P. vivax in 2588 blood samples
collected from 9 Sub-Saharan African countries, including 851
from the Republic of Congo [16]. This might simply reflect the
fact that most of the DNA templates were extracted from archival
blood dried on filter paper, and might have corresponded to a
small volume of blood (,1 ml), which would reduce the sensitivity
for the detection of sub-microscopic infections. Alternatively, it
might be due to the lower frequencies of Duffy positive individuals
in these countries (,5%), though this would seem to contradict the
high proportion of persons (13%) who have been exposed to P.
vivax-infected mosquito bites [17], which implies a relatively high
proportion of P. vivax carriers in the community.
It should be noted that the three pregnant women had not
reported any clinical symptoms on the days when the blood samples
analysedwerefoundtobepositiveforP.vivaxbyPCRanalysis.Thisis
consistent with the fact that the P. vivax parasitaemias were in most
cases below the threshold of microscopic detection. Such low-grade
chronic infections might indicate a certain level of immunity to P.
vivax, and/or might be due to a reduction of erythrocyte susceptibility
to P. vivax in Duffy negative heterozygotes [19]. Nonetheless, the fact
that the infections were detected in pregnant women is a cause for
concern, because P. vivax during pregnancy has been shown to be
associated with maternal anaemia and low birth-weight [20]. In this
context, the finding of Pvdhfr mutations associated with resistance to
pyrimethamine is noteworthy,as it might indicate that the selection of
pyrimethamine-resistant P. vivax has been underway in Uganda for
sometime.WhetherthefailureofSPtreatmenttoclearP.vivax(Fig.1)
was due to these mutations or the shorter half-life of both drugs in
pregnant women [21] remains to be determined.
As it stands, the prevalence of malaria in the residents of
Mbarara District cannot be estimated from samples collected only
from a cohort of pregnant women. These samples are further
biased by the fact that a subset of these women was specifically
recruited for a study of drug efficacy against P. falciparum infection
[22]. P. falciparum remains by far the dominant species observed by
microscopy in Uganda. This is also the case for the samples
collected from the pregnant women in our cohort. For example of
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detected alone in 196 smears, whereas P. ovale and P. vivax were
observed alone in only 4 and 2 smears, respectively. Mixed species
infections, in all cases with P. falciparum, were found in 7 of these
smears (3 with P. malariae, and 4 with P. vivax). Given that several
thousand samples were collected from the women of this cohort, a
large-scale PCR analysis of all the samples available was precluded
on grounds of cost. Nonetheless, in a concurrent longitudinal study
evaluating rapid diagnostic tools for malaria in a subset of 96
pregnant women from the same cohort, 484 samples were
collected and PCR analysis revealed 79 samples with pure P.
falciparum infections, and only 2 with P. malariae and 1 with P. ovale,
but none with P. vivax. Nonetheless, it is unlikely that the P. vivax
prevalence in the community would be negligible. First, the
percentage of Duffy positive individuals (13%) is relatively high.
Second, in two of the women P. vivax was repeatedly detected by
PCR in blood samples collected during follow-up (either due to
recrudescences/relapses or to reinfections). Such a chronic
infection constitutes a sustained reservoir of infection that would
increase the potential for transmission. At present, it is not known
whether pregnant women in Africa are more susceptible to P. vivax
than others in the community, as is the case for those in India [23]
or in Thailand [24]. This will have to await PCR analysis of
samples collected from the community at large.
In conclusion, we present evidence consistent with stable
transmission of P. vivax infections sustained in a predominantly
Duffy negative population in south-western Uganda. These
observations lend credence to previous reports of P. vivax infections
in residents of western and central Africa, and explain the
relatively high frequencies of P. vivax imported with travellers
returning from these regions. If the P. vivax infections in sub-
Saharan Africa are generally low grade and asymptomatic, then it
is likely that the prevalence of P. vivax will be inaccurate when
based only on results from microscopic examination of smears
Figure 1. Data for the samples collected from the three women found infected with P. vivax. Days when treatment with artemether-
lumefantrine (CoA) or IPTp using sulfadoxine-pyrimethamine (SP) was administered are indicated. Del denoted the day of delivery. Samples for PCR or
thick blood smears (TBS) were only available for the weeks indicated on the time axis, and the results are presented above this axis. The parasite
species identified by PCR or microscopy are provided, as is the average parasitaemia (parasites per ml of blood) recorded for each species: F=P.
falciparum;V=P. vivax (shown in red); O=P. ovale; N=negative sample, and ‘‘-‘‘ denotes a missing sample. The patient codes provided are those
internally and randomly assigned upon recruitment. Samples from patient C012080 from which the Pvdhfr fragment could be amplified and
sequenced are indicated by an asterisk (*).
doi:10.1371/journal.pone.0019801.g001
Plasmodium vivax Transmission in Uganda
PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e19801collected for passive case detection. Clearly further detailed
investigations of the epidemiology of P. vivax in the largely Duffy
negative Sub-Saharan African populations are warranted. It might
lead this species to be taken into consideration when planning for
malaria elimination in Sub-Saharan Africa. In this context, the use
of primaquine, the only drug available to eliminate P. vivax
hypnozoites, poses a particular challenge in an African setting
where the prevalence of glucose-6-phosphate deficient inhabitants
severely limits its deployment.
Materials and Methods
Cohort, sample collection
A cohort of African Ugandan pregnant women (n=1229)
within a radius of 15 km from Mbarara town in south-western
Uganda was recruited between October 2006 and January 2009
for investigations of malaria in pregnancy and its treatment [22],
with blood samples collected periodically for blood smears and
dried blood spots on filter paper (Whatman 3 MM). A sub-cohort
was also followed with weekly blood samples collected by
fingerprick, or by venepuncture if other tests were being
performed [22], with EDTA as anticoagulant.
Blood samples were used to prepare blood smears, filter paper
spots or to separate red blood cells (RBCs). An aliquot of the blood
collected on EDTA was centrifuged to obtain a RBC pellet that
was stored at 280uC until further analysis.
Microscopy
Two hundred high power fields (10006)o fe a c hG i e m s a -
s t a i n e dt h i c kb l o o ds m e a r( T B S )w e r er e a db e f o r ed e c l a r i n gt h e
slide negative. Positive slides and 10% of all negative slides were
examined by two independent microscopists for the purposes of
internal quality control, and a third read was performed in cases
of discordance (positive/negative, parasitaemia variation
.50%, and species). Average parasitaemia from the two closest
results was estimated by counting parasites against 200 white
blood cells (a figure increased to 500 if #9p a r a s i t e sw e r e
observed initially) and by assuming an average WBC count of
8000 per mL.
Molecular analysis
The presence and identity of the four Plasmodium species that
infect humans in Africa was established using a nested PCR
protocol [25], with minor modification to allow detection of the
two P. ovale types [26]. The primary PCR reaction was initiated
either: 1) with DNA extracted from the filter spots on which the
finger prick blood was dried using commercial kits (Qiagen
DNAMicro, Qiagen, Germany); or 2) directly on a pellet derived
from a 5 ml aliquot of the frozen RBCs (equivalent to 10 mlo f
whole blood), obtained by centrifugation of a lysate of these cells
after suspension in phosphate buffered saline (PBS) supplemented
with 0.05% w/v saponin and a further centrifugation step to
recover the pellet after washing in PBS [27].
A fragment of the Pvdhfr-ts gene was amplified as by nested PCR
as previously described [18], using the primers VDT-OF (59-
ATGGAGGACCTTTCAGATGTATTTGACATT) + VDT-
OR (59-GGCGGCCATCTCCATGGTTATTTTATCGTG) for
the primary reactions, and VDT-OF + VDT-LiF (59-CTTC-
CCCGAGTTTGACGAAAGCCAGTTTCG) for the secondary
reaction. The amplified fragment was cloned into a pCR4-Topo
vector (Invitrogen, The Netherland), sequenced commercially, and
the sequences assembled and analyzed using the Lasergene suite of
programs (DNASTAR Inc, USA).
The Duffy status was determined based on restriction fragment
length polymorphism (RFLP) of two PCR fragments as described
previously [19,28] obtained by nested PCR using FY277 (59-
CAGGAAGACCCAAGGCCAG) + FY851 (59-GGCCAAGA-
CGGGCACCACAATG) for the primary reaction and FY277 +
FYPdn (59-CCATGGCACCGTTTGGTTCAGG) or FY851 +
FYup (59-GACTCTTCCGGTGTAACTCTGATG) for the sec-
ondary reaction. The amplified fragments were then digested with
the appropriate restriction enzymes and product sizes were
determined after agarose gel electrophoresis.
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